---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-125933"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:53:50.937372+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CalciMedica reports Q3 net loss $5.6M, completes $10.2M offering; cash runway into H1 2026

## Summary
- Q3 2024 net loss $5.6M ($0.50/sh); total loss from operations $5.7M.
- Cash $14.6M at Sep 30; pro forma after Oct offering ~$23.7M, funds ops into H1 2026.
- Completed Nov 1 public offering: 2.72M shares at $3.75, gross proceeds $10.2M.
- Phase 2b CARPO: win ratio 1.64 (p=0.0372) for high-dose Auxora vs placebo; 100% relative risk reduction in new-onset severe respiratory failure.
- Expects Phase 3 start in 2025; topline data from KOURAGE (AKI) and CRSPA (AIPT) trials in 2025.

## SEC filing metadata
- accession: 0000950170-24-125933
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000095017024125933/0000950170-24-125933-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000095017024125933/ck0001534133-20241113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-125933
- JSON: https://secwatch.observer/filing/0000950170-24-125933.json
- Plain text: https://secwatch.observer/filing/0000950170-24-125933.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.